Literature DB >> 23261525

The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.

Karthika Natarajan1, Jasjeet Bhullar, Suneet Shukla, Mehmet Burcu, Zhe-Sheng Chen, Suresh V Ambudkar, Maria R Baer.   

Abstract

Overexpression of the ATP-binding cassette (ABC) drug efflux proteins P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on malignant cells is associated with inferior chemotherapy outcomes. Both, ABCB1 and ABCG2, are substrates of the serine/threonine kinase Pim-1; Pim-1 knockdown decreases their cell surface expression, but SGI-1776, the first clinically tested Pim inhibitor, was shown to reverse drug resistance by directly inhibiting ABCB1-mediated transport. We sought to characterize Pim-1-dependent and -independent effects of SGI-1776 on drug resistance. SGI-1776 at the Pim-1-inhibitory and non-cytotoxic concentration of 1 μM decreased the IC(50)s of the ABCG2 and ABCB1 substrate drugs in cytotoxicity assays in resistant cells, with no effect on the IC(50) of non-substrate drug, nor in parental cells. SGI-1776 also increased apoptosis of cells overexpressing ABCG2 or ABCB1 exposed to substrate chemotherapy drugs and decreased their colony formation in the presence of substrate, but not non-substrate, drugs, with no effect on parental cells. SGI-1776 decreased ABCB1 and ABCG2 surface expression on K562/ABCB1 and K562/ABCG2 cells, respectively, with Pim-1 overexpression, but not HL60/VCR and 8226/MR20 cells, with lower-level Pim-1 expression. Finally, SGI-1776 inhibited uptake of ABCG2 and ABCB1 substrates in a concentration-dependent manner irrespective of Pim-1 expression, inhibited ABCB1 and ABCG2 photoaffinity labeling with the transport substrate [(125)I]iodoarylazidoprazosin ([(125)I]IAAP) and stimulated ABCB1 and ABCG2 ATPase activity. Thus SGI-1776 decreases cell surface expression of ABCB1 and ABCG2 and inhibits drug transport by Pim-1-dependent and -independent mechanisms, respectively. Decrease in ABCB1 and ABCG2 cell surface expression mediated by Pim-1 inhibition represents a novel mechanism of chemosensitization.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23261525      PMCID: PMC3821043          DOI: 10.1016/j.bcp.2012.12.006

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  62 in total

1.  miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.

Authors:  Anna M Eiring; Jason G Harb; Paolo Neviani; Christopher Garton; Joshua J Oaks; Riccardo Spizzo; Shujun Liu; Sebastian Schwind; Ramasamy Santhanam; Christopher J Hickey; Heiko Becker; Jason C Chandler; Raul Andino; Jorge Cortes; Peter Hokland; Claudia S Huettner; Ravi Bhatia; Denis C Roy; Stephen A Liebhaber; Michael A Caligiuri; Guido Marcucci; Ramiro Garzon; Carlo M Croce; George A Calin; Danilo Perrotti
Journal:  Cell       Date:  2010-03-05       Impact factor: 41.582

2.  Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.

Authors:  Jurjen S Lagas; Robert A B van Waterschoot; Vicky A C J van Tilburg; Michel J Hillebrand; Nienke Lankheet; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

3.  Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes.

Authors:  Shannon M Mumenthaler; Patricia Y B Ng; Amanda Hodge; David Bearss; Gregory Berk; Sarath Kanekal; Sanjeev Redkar; Pietro Taverna; David B Agus; Anjali Jain
Journal:  Mol Cancer Ther       Date:  2009-10       Impact factor: 6.261

Review 4.  Understanding polyspecificity of multidrug ABC transporters: closing in on the gaps in ABCB1.

Authors:  Daniel A P Gutmann; Andrew Ward; Ina L Urbatsch; Geoffrey Chang; Hendrik W van Veen
Journal:  Trends Biochem Sci       Date:  2009-10-12       Impact factor: 13.807

5.  Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.

Authors:  Lisa S Chen; Sanjeev Redkar; David Bearss; William G Wierda; Varsha Gandhi
Journal:  Blood       Date:  2009-09-04       Impact factor: 22.113

6.  Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.

Authors:  Suneet Shukla; Robert W Robey; Susan E Bates; Suresh V Ambudkar
Journal:  Drug Metab Dispos       Date:  2008-10-29       Impact factor: 3.922

7.  Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2.

Authors:  S Shukla; Z E Sauna; S V Ambudkar
Journal:  Leukemia       Date:  2007-08-09       Impact factor: 11.528

8.  The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells.

Authors:  Yingqiu Xie; Kexin Xu; Douglas E Linn; Xi Yang; Zhiyong Guo; Hermela Shimelis; Takeo Nakanishi; Douglas D Ross; Hegang Chen; Ladan Fazli; Martin E Gleave; Yun Qiu
Journal:  J Biol Chem       Date:  2007-12-05       Impact factor: 5.157

9.  Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation.

Authors:  Jurjen S Lagas; Robert A B van Waterschoot; Rolf W Sparidans; Els Wagenaar; Jos H Beijnen; Alfred H Schinkel
Journal:  Mol Cancer Ther       Date:  2010-01-26       Impact factor: 6.261

10.  Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.

Authors:  Amit K Tiwari; Kamlesh Sodani; Si-Rong Wang; Ye-Hong Kuang; Charles R Ashby; Xiang Chen; Zhe-Sheng Chen
Journal:  Biochem Pharmacol       Date:  2009-04-11       Impact factor: 5.858

View more
  25 in total

1.  The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.

Authors:  Sung-Han Hsiao; Sabrina Lusvarghi; Yang-Hui Huang; Suresh V Ambudkar; Sheng-Chieh Hsu; Chung-Pu Wu
Journal:  Cancer Lett       Date:  2019-01-11       Impact factor: 8.679

2.  Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo.

Authors:  Kamlesh Sodani; Atish Patel; Nagaraju Anreddy; Satyakam Singh; Dong-Hua Yang; Rishil J Kathawala; Priyank Kumar; Tanaji T Talele; Zhe-Sheng Chen
Journal:  Biochem Pharmacol       Date:  2014-02-22       Impact factor: 5.858

3.  Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.

Authors:  Chung-Pu Wu; Sabrina Lusvarghi; Jyun-Cheng Wang; Sung-Han Hsiao; Yang-Hui Huang; Tai-Ho Hung; Suresh V Ambudkar
Journal:  Mol Pharm       Date:  2019-06-04       Impact factor: 4.939

4.  Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.

Authors:  Lisa S Chen; Ji-Yeon Yang; Han Liang; Jorge E Cortes; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2016-04-07

Review 5.  Beyond Competitive Inhibition: Regulation of ABC Transporters by Kinases and Protein-Protein Interactions as Potential Mechanisms of Drug-Drug Interactions.

Authors:  Rebecca R Crawford; Praveen K Potukuchi; Erin G Schuetz; John D Schuetz
Journal:  Drug Metab Dispos       Date:  2018-03-07       Impact factor: 3.922

6.  Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.

Authors:  Chung-Pu Wu; Sabrina Lusvarghi; Sung-Han Hsiao; Te-Chun Liu; Yan-Qing Li; Yang-Hui Huang; Tai-Ho Hung; Suresh V Ambudkar
Journal:  J Nat Prod       Date:  2020-04-29       Impact factor: 4.050

7.  SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines.

Authors:  Chung-Pu Wu; Megumi Murakami; Sung-Han Hsiao; Te-Chun Liu; Ni Yeh; Yan-Qing Li; Tai-Ho Hung; Yu-Shan Wu; Suresh V Ambudkar
Journal:  Cancer Lett       Date:  2018-07-06       Impact factor: 8.679

8.  Pim-1 kinase as cancer drug target: An update.

Authors:  Yernar Tursynbay; Jinfu Zhang; Zhi Li; Tursonjan Tokay; Zhaxybay Zhumadilov; Denglong Wu; Yingqiu Xie
Journal:  Biomed Rep       Date:  2015-12-24

9.  The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines.

Authors:  Sung-Han Hsiao; Megumi Murakami; Ni Yeh; Yan-Qing Li; Tai-Ho Hung; Yu-Shan Wu; Suresh V Ambudkar; Chung-Pu Wu
Journal:  Cancer Lett       Date:  2018-07-18       Impact factor: 8.679

10.  Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines.

Authors:  Chung-Pu Wu; Sung-Han Hsiao; Megumi Murakami; Ming-Jie Lu; Yan-Qing Li; Chia-Hung Hsieh; Suresh V Ambudkar; Yu-Shan Wu
Journal:  Cancer Lett       Date:  2017-09-08       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.